Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2016

View Archived Issues

Phase III trial to establish biosimilarity of SB8 to bevacizumab

Sarepta Therapeutics initiates phase III trial of SRP-4045 and SRP-4053 for the treatment of DMD

FDA grants emergency use authorization for Zika virus molecular detection assay

GVK Biosciences patents TrKA inhibitors

Arvinas discloses PROTAC compounds

Johns Hopkins University describes agents for the treatment of cancer

Newave Pharmaceutical develops FGFR4 inhibitors

Oncbiomune Pharmaceuticals enrolls patients for phase Ia study of Proscavax

University of Washington presents micro-dystrophins

Antibe Therapeutics completes phase II trial of ATB-346

Lycera begins enrollment in phase II trial of LYC-30937-EC in active ulcerative colitis

Armanezumab shows promise for AD

Immune mechanisms of the Mtb deltappe25-pe19 vaccine candidate

BioLineRx collaborates with MD Anderson Cancer Center for phase II study of BL-8040

Windtree receives grant to support Aerosurf phase IIb trial

Valeant licenses rights to develop and commercialize NER-1006 from Norgine

Alkermes submits sNDA to FDA for extended-release formulation of Aristada

Coherus BioSciences reports topline results for phase III study of CHS-1420

Selumetinib does not meet primary endpoint in phase III SELECT-1 trial

Proteostasis Therapeutics completes key preclinical milestone in collaboration with Astellas

Scintilla Pharmaceuticals acquires Scilex Pharmaceuticals to bolster pain management business

COMP grants orphan drug designation to AB Science's masitinib in ALS

FDA confirms sufficient data to advance E-2609 into phase III studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...